NW PHARMATECH IS DEDICATED TO IMPROVING PATIENTS’ LIVES
by delivering the therapeutic potential of natural compounds via a new generation of drug formulation design.
About NW PharmaTech
NW PharmaTech is a biotech company revolutionising the treatment of psychiatric & neurological disorders.
Our ‘Nature to Medicine’ approach involves leveraging our patented drug delivery technology to optimise naturally-derived compounds, such as cannabidiol, for therapeutic purposes.
With a solid scientific foundation and an expert team in the pharmaceutical, life sciences & cannabinoid sectors, we are bringing to market a portfolio of innovative medicines.
Mental health is a complex and underserved global pandemic, further exacerbated by COVID-19.
Many of the solutions available to patients today are poor as drugs often come with unwanted side effects or lack of efficacy. In the meantime nature produces a range of compounds with properties that are uniquely specific to affect the human mind and body in the most profound ways.
Many of these natural compounds possess vast therapeutic potential to aid a vast number of patients suffering from debilitating mental health conditions, and help them return towards a state of homeostasis, thereby allowing them to live longer and happier lives.
Our mission is to identify and deliver the therapeutic potential of these compounds to patients, via a new generation of drug formulation design.
We plan to achieve this through a strategy rooted in rigorous science and a best-in-class team with long standing expertise in the pharmaceutical, life sciences and cannabinoid sectors.
Our patented drug delivery technology allows us to harness the benefits of natural compounds, whilst providing a route to defensible commercialisation.
THE MENTAL HEALTH PANDEMIC IN NUMBERS
The G7 countries spend $3.9tn per annum on mental health (8.9% of overall health spending)1
1: Data from OECD (data.oecd.org) and World Health Organization (who.int/data/gho)
2: “Epidemiology of anxiety disorders in the 21st century”, Dialogues in Clinical Neuroscience, Borwin Bandelow et al., 2015
3: “Economic costs of anxiety disorders”, Anxiety vol. 2,4 (1996), R L DuPont et al., 1996
4: ”Understanding Psychosis”, National Institute of Mental Health, NIH Publication No. 20-MH-8110, 2020
5: “Societal Costs of Schizophrenia & Related Disorders”, Schizophrenia & Psychosis Action Alliance, Publication July 2021
6: “Insomnia Overview: Epidemiology, Pathophysiology, Diagnosis and Monitoring, and Nonpharmacologic Therapy”, AJMC, Julie Dopheide, 2020
7: “Why Sleep Matters—The Economic Costs of Insufficient Sleep”, Rand Health Quarterly, Marco Hafner et al., 2017